Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.

Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke JA, Bosso D, Milowsky MI, Witek MS, Battaglia M, Pignata S, Cherhroudi C, Cox ME, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl BJ, Di Lorenzo G.

Oncotarget. 2018 Apr 13;9(28):19861-19873. doi: 10.18632/oncotarget.24888. eCollection 2018 Apr 13.

2.

The impact of time to metastasis on overall survival in patients with prostate cancer.

Frees S, Akamatsu S, Bidnur S, Khalaf D, Chavez-Munoz C, Struss W, Eigl BJ, Gleave M, Chi KN, So A.

World J Urol. 2018 Jul;36(7):1039-1046. doi: 10.1007/s00345-018-2236-4. Epub 2018 Feb 27.

PMID:
29488095
3.

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209.

Eigl BJ, Chi K, Tu D, Hotte SJ, Winquist E, Booth CM, Canil C, Potvin K, Gregg R, North S, Zulfiqar M, Ellard S, Ruether JD, Le L, Kakumanu AS, Salim M, Allan AL, Feilotter H, Theis A, Seymour L.

Oncotarget. 2018 Jan 17;9(8):8155-8164. doi: 10.18632/oncotarget.24263. eCollection 2018 Jan 30.

4.

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Khalaf DJ, Avilés CM, Azad AA, Sunderland K, Todenhöfer T, Eigl BJ, Finch D, Le L, Atwell A, Keith B, Kollmannsberger C, Chi KN.

Can Urol Assoc J. 2018 Feb;12(2):E47-E52. doi: 10.5489/cuaj.4600. Epub 2017 Dec 1.

5.

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.

Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN.

Cancer Discov. 2018 Apr;8(4):444-457. doi: 10.1158/2159-8290.CD-17-0937. Epub 2018 Jan 24.

PMID:
29367197
6.

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.

Bellmunt J, Eigl BJ, Senkus E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar SS, Sternberg CN, Retz M, Pal S, Blumenstein B, Jacobs C, Stewart PS, Petrylak DP.

Ann Oncol. 2017 Oct 1;28(10):2481-2488. doi: 10.1093/annonc/mdx400.

PMID:
28961845
7.

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.

Vandekerkhove G, Todenhöfer T, Annala M, Struss WJ, Wong A, Beja K, Ritch E, Brahmbhatt S, Volik SV, Hennenlotter J, Nykter M, Chi KN, North S, Stenzl A, Collins CC, Eigl BJ, Black PC, Wyatt AW.

Clin Cancer Res. 2017 Nov 1;23(21):6487-6497. doi: 10.1158/1078-0432.CCR-17-1140. Epub 2017 Jul 31.

PMID:
28760909
8.

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.

Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K; Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group.

Eur Urol Focus. 2017 Jun 3. pii: S2405-4569(17)30125-6. doi: 10.1016/j.euf.2017.05.006. [Epub ahead of print]

PMID:
28753897
9.

Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets.

Necchi A, Eigl BJ, Yang ES, Bae S, Chandrashekar D, Chen D, Naik G, Mehta A, Giannatempo P, Colecchia M, Gordetsky J, Wei S, Cooper T, Varambally S, Sonpavde G.

Eur Urol Focus. 2016 Aug 27. pii: S2405-4569(16)30109-2. doi: 10.1016/j.euf.2016.08.001. [Epub ahead of print]

10.

Expanding Immunotherapy Options for Bladder Cancer: Commentary on: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Lavoie JM, Bidnur S, Black PC, Eigl BJ.

Urology. 2017 Aug;106:1-2. doi: 10.1016/j.urology.2017.04.001. Epub 2017 Apr 25. No abstract available.

PMID:
28454987
11.

Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis.

Necchi A, Pond GR, Raggi D, Ottenhof SR, Djajadiningrat RS, Horenblas S, Khoo V, Hakenberg OW, Draeger D, Protzel C, Heidenreich A, Haidl F, Eigl BJ, Nappi L, Matsumoto K, Vaishampayan U, Woods ME, Salvioni R, Nicolai N, Catanzaro M, Giannatempo P, Geynisman DM, Preto M, Xylinas E, Milowsky MI, De Placido S, Di Lorenzo G, Sonpavde G.

Clin Genitourin Cancer. 2017 Oct;15(5):548-555.e3. doi: 10.1016/j.clgc.2017.02.002. Epub 2017 Feb 27.

PMID:
28325636
12.

A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer.

Tsang ES, de Haan M, Eigl BJ.

J Oncol Pharm Pract. 2018 Mar;24(2):143-145. doi: 10.1177/1078155216689381. Epub 2017 Feb 1.

PMID:
28147927
13.

Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study.

Buonerba C, Di Lorenzo G, Pond G, Cartenì G, Scagliarini S, Rozzi A, Quevedo FJ, Dorff T, Nappi L, Lanzetta G, Pagliaro L, Eigl BJ, Naik G, Ferro M, Galdiero M, De Placido S, Sonpavde G.

Front Pharmacol. 2016 Dec 20;7:487. doi: 10.3389/fphar.2016.00487. eCollection 2016.

14.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group.

Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8.

15.

Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).

Parimi S, Eliasziw M, North S, Trudeau M, Winquist E, Chi KN, Ruether D, Cheng T, Eigl BJ.

Invest New Drugs. 2016 Dec;34(6):771-776. Epub 2016 Aug 26.

PMID:
27565809
16.

AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.

Todenhöfer T, Azad A, Stewart C, Gao J, Eigl BJ, Gleave ME, Joshua AM, Black PC, Chi KN.

J Urol. 2017 Jan;197(1):135-142. doi: 10.1016/j.juro.2016.06.094. Epub 2016 Jul 17.

PMID:
27436429
17.

Building the Case for Adjuvant Chemotherapy After Radical Cystectomy: Commentary on: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer.

Nappi L, Black PC, Eigl BJ.

Urology. 2016 Aug;94:1-2. doi: 10.1016/j.urology.2016.03.033. Epub 2016 Apr 1. No abstract available.

PMID:
27045709
18.

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.

Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, Rathkopf DE, Fizazi K, Kantoff PW, Li J, Azad AA, Eigl BJ, Heng DY, Joshua AM, de Bono JS, Scher HI.

Ann Oncol. 2016 Mar;27(3):454-60. doi: 10.1093/annonc/mdv594. Epub 2015 Dec 18.

19.

Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.

Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Di Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Pal S, Eigl BJ.

Clin Genitourin Cancer. 2016 Aug;14(4):331-40. doi: 10.1016/j.clgc.2015.10.005. Epub 2015 Oct 24.

PMID:
26589729
20.

Localized prostate cancer presenting as a renal pseudo-tumour.

Poonja Z, So A, Eigl BJ.

Can Urol Assoc J. 2015 Jul-Aug;9(7-8):E505-6. doi: 10.5489/cuaj.2950.

21.

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.

Eigl BJ, North S, Winquist E, Finch D, Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, Bazov J, Jamaspishvili T, Cox ME, Bradbury PA, Eisenhauer EA, Chi KN.

Invest New Drugs. 2015 Aug;33(4):969-76. doi: 10.1007/s10637-015-0252-4. Epub 2015 May 19.

PMID:
25983041
22.

Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.

Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G.

Clin Genitourin Cancer. 2015 Apr;13(2):178-84. doi: 10.1016/j.clgc.2014.08.010. Epub 2014 Sep 23.

23.

Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists.

Hsu T, Black PC, Chi KN, Canil CM, Eigl BJ, Kulkarni G, North S, Wood L, Zlotta AR, Lau A, Panzarella T, Sridhar SS.

Can Urol Assoc J. 2014 Sep;8(9-10):309-16. doi: 10.5489/cuaj.2111.

25.

A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.

Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN.

Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872. Epub 2014 Aug 29.

PMID:
25175831
26.

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.

Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN.

Eur Urol. 2015 Jan;67(1):23-29. doi: 10.1016/j.eururo.2014.06.045. Epub 2014 Jul 10.

PMID:
25018038
27.

Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma.

Pond GR, Milowsky MI, Kolinsky MP, Eigl BJ, Necchi A, Harshman LC, Di Lorenzo G, Dorff TB, Lee RJ, Sonpavde G.

Clin Genitourin Cancer. 2014 Dec;12(6):440-6. doi: 10.1016/j.clgc.2014.03.009. Epub 2014 Mar 27.

PMID:
24787971
28.

Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.

Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, Clayton R, Heng DY, Joshua AM, Chi KN.

Eur Urol. 2015 Mar;67(3):441-7. doi: 10.1016/j.eururo.2014.01.030. Epub 2014 Jan 31.

PMID:
24508071
29.

Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.

Pond GR, Di Lorenzo G, Necchi A, Eigl BJ, Kolinsky MP, Chacko RT, Dorff TB, Harshman LC, Milowsky MI, Lee RJ, Galsky MD, Federico P, Bolger G, DeShazo M, Mehta A, Goyal J, Sonpavde G.

Urol Oncol. 2014 May;32(4):501-8. doi: 10.1016/j.urolonc.2013.10.007. Epub 2013 Dec 12.

PMID:
24332646
30.

Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome?

Azad AA, Eigl BJ.

Eur Urol. 2014 Feb;65(2):504-5. doi: 10.1016/j.eururo.2013.10.035. Epub 2013 Nov 1. No abstract available.

PMID:
24210911
31.

Incremental costs of prostate cancer trials: Are clinical trials really a burden on a public payer system?

Jones B, Syme R, Eliasziw M, Eigl BJ.

Can Urol Assoc J. 2013 Mar-Apr;7(3-4):E231-6. doi: 10.5489/cuaj.11302.

32.

The future of systemic therapies for localised prostate cancer.

Eigl BJ, Gleave ME, Chi KN.

Clin Oncol (R Coll Radiol). 2013 Aug;25(8):506-13. doi: 10.1016/j.clon.2013.04.002. Epub 2013 May 7. Review.

PMID:
23660300
33.

Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors.

Jimeno A, Weiss GJ, Miller WH Jr, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM.

Clin Cancer Res. 2013 May 15;19(10):2766-74. doi: 10.1158/1078-0432.CCR-12-3654. Epub 2013 Apr 10.

34.

Targeting the apoptosis pathway in prostate cancer.

Zielinski RR, Eigl BJ, Chi KN.

Cancer J. 2013 Jan-Feb;19(1):79-89. doi: 10.1097/PPO.0b013e3182801cf7. Review.

PMID:
23337761
35.

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a.

Chi KN, Beardsley E, Eigl BJ, Venner P, Hotte SJ, Winquist E, Ko YJ, Sridhar SS, Weber D, Saad F.

Ann Oncol. 2012 Jan;23(1):53-8. doi: 10.1093/annonc/mdr336. Epub 2011 Jul 16.

PMID:
21765178
36.

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA.

J Clin Oncol. 2010 Sep 20;28(27):4247-54. doi: 10.1200/JCO.2009.26.8771. Epub 2010 Aug 23.

PMID:
20733135
37.

Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline.

Miles BJ, Fairey AS, Eliasziw M, Estey EP, Venner P, Finch D, Trpkov K, Eigl BJ.

Can Urol Assoc J. 2010 Aug;4(4):263-7.

38.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK.

J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13.

PMID:
19826129
39.

Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.

Vickers MM, Heng DY, Hemmelgarn B, Eigl BJ.

Clin Genitourin Cancer. 2009 Oct;7(3):E104-6. doi: 10.3816/CGC.2009.n.035.

PMID:
19815480
40.

Prostate cancer with tertiary Gleason pattern 5 in prostate needle biopsy: clinicopathologic findings and disease progression.

Trpkov K, Zhang J, Chan M, Eigl BJ, Yilmaz A.

Am J Surg Pathol. 2009 Feb;33(2):233-40. doi: 10.1097/PAS.0b013e31817fb3bd.

PMID:
18936690
41.

Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study.

Wu JS, Monk G, Clark T, Robinson J, Eigl BJ, Hagen N.

Clin Oncol (R Coll Radiol). 2006 Sep;18(7):539-44.

PMID:
16969984
42.

Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.

Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME.

Clin Cancer Res. 2005 Jul 1;11(13):4905-11.

43.

Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis.

Karsan A, Eigl BJ, Flibotte S, Gelmon K, Switzer P, Hassell P, Harrison D, Law J, Hayes M, Stillwell M, Xiao Z, Conrads TP, Veenstra T.

Clin Chem. 2005 Aug;51(8):1525-8. Epub 2005 Jun 10. No abstract available.

Supplemental Content

Support Center